A Digital Assay to Streamline PD-L1 IHC: Published in Scientific Reports

Flagship Biosciences, Inc., today announced the publication of a paper describing validation of a novel digital spatial biology assay in Scientific Reports. The assay, Tissue Insight (TI) 22C3 NSCLC, surpasses manual scoring in PD-L1 positive tumor samples.

Modern cancer immunotherapy for non-small cell lung cancer (NSCLC) utilizes programmed death-ligand 1 (PD-L1) checkpoint inhibitors. Monitoring patient response to checkpoint inhibitor therapies often involves the use of immunohistochemistry (IHC) to determine the level of PD-L1 expression in tumor tissues. However, this quantification is time consuming, and interpretation is often variable for pathologists: traditional manual reads may not fully recognize the complex interaction between tumor cells and the surrounding immune microenvironment, which limits the prediction of PD-L1 inhibitor outcomes and patient response…